You just read:

REGENXBIO Reports Second Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD

News provided by

REGENXBIO Inc.

Aug 07, 2019, 16:05 ET